{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":24,"n_cols":5,"rows_kept":24,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[12,2,12,3],[13,2,13,3],[17,2,17,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910778679103321"]
[null,null,"Titolo",null,"Vaccine supply and innovation [[electronic resource] /] / Division of Health Promotion and Disease Prevention, Institute of Medicine"]
[null,null,"Pubbl/distr/stampa",null,"Washington, D.C., : National Academy Press, 1985"]
[null,null,"ISBN",null,"1-280-24677-4"]
[{"$nulls":4},"9786610246779"]
[{"$nulls":4},"0-309-58152-4"]
[{"$nulls":4},"0-585-14491-5"]
[null,null,"Descrizione fisica",null,"1 online resource (210 p.)"]
[null,null,"Collana",null,"Publication IOM ; ; no. 85-02"]
[null,null,"Disciplina",null,"338.47615372"]
[null,null,"Soggetti",null,"Vaccines - Research"]
[{"$nulls":4},"Immunization"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"\"\"Vaccine Supply and Innovation\"\"; \"\"Copyright\"\"; \"\"Preface\"\"; \"\"Contents\"\"; \"\"Vaccine Supply and Innovation\"\"; \"\"1 Summary\"\"; \"\"OVERVIEW\"\"; \"\"VACCINE AVAILABILITY: MAJOR BARRIERS AND IMPEDIMENTS\"\"; \"\"Impediments to Vaccine Innovation\"\"; \"\"ECONOMIC CHARACTERISTICS OF THE VACCINE INDUSTRY\"\"; \"\"VACCINE INJURY\"\"; \"\"THE LEGAL SITUATION AND ITS CONSEQUENCES\"\"; \"\"CONSEQUENCES OF THE STATE OF VACCINE INJURY LIABILITY LAW FOR VACCINE PRODUCTION AND INNOVATION\"\"; \"\"A NATIONAL VACCINE COMMISSION\"\"; \"\"COMPENSATION AND LIABILITY FOR VACCINE-RELATED INJURY\"\"; \"\"2 Vaccines: Past, Present, and Future\"\""]
[{"$nulls":4},"\"\"TYPES OF IMMUNIZATION\"\"\"\"HISTORY OF IMMUNIZATION\"\"; \"\"THE PRESENT\"\"; \"\"Development of Vaccines and Recommendations for Vaccine Use\"\"; \"\"THE FUTURE\"\"; \"\"REFERENCES AND NOTES\"\"; \"\"3 Vaccine Availability: Concerns, Barriers, and Impediments\"\"; \"\"CONCERNS ABOUT THE CURRENT SITUATION\"\"; \"\"Supply\"\"; \"\"Stockpiling of Vaccines\"\"; \"\"Problems with Sole Reliance on Foreign Manufacturers\"\"; \"\"Federal Action to Ensure Vaccine Supply\"\"; \"\"BARRIERS AND IMPEDIMENTS TO VACCINE INNOVATION\"\"; \"\"Identification of Need and Establishing Priorities\"\""]
[{"$nulls":4},"\"\"Establishing the Technical Feasibility of Vaccine Development\"\"\"\"Economic Disincentives to Innovation and Production\"\"; \"\"Factors Influencing the Market for Vaccines\"\"; \"\"VACCINE UTILIZATION\"\"; "]
[{"$nulls":4},"\"\"System Factors\"\"; \"\"Client Factors\"\"; \"\"Provider Factors\"\"; \"\"CONCLUSIONS\"\"; \"\"Barriers and Impediments to Vaccine Innovation\"\"; \"\"REFERENCES AND NOTES\"\"; \"\"4 Economic Aspects of Vaccine Innovation and Manufacturing\"\"; \"\"POTENTIAL CAUSES OF INDUSTRY DECLINE\"\"; \"\"Property Rights and Innovation\"\"; \"\"Regulation\"\"; \"\"Market Size\"\"; \"\"Liability and Risk\"\"; \"\"DESCRIPTIVE STATISTICS\"\""]
[{"$nulls":4},"\"\"The Market and Participants\"\"\"\"Pricing\"\"; \"\"Research and Development\"\"; \"\"CONCLUSIONS\"\"; \"\"REFERENCES AND NOTES\"\"; \"\"5 Vaccine Injury\"\"; \"\"The Pertussis Controversy\"\"; \"\"Identifying Individuals at High Risk of Adverse Effects\"\"; \"\"VACCINES USED IN CHILDHOOD\"\"; \"\"Pertussis Vaccine\"\"; \"\"Diphtheria Toxoid\"\"; \"\"Tetanus Toxoid\"\"; \"\"Poliomyelitis Vaccines\"\"; \"\"Measles Vaccine\"\"; \"\"Rubella Vaccine\"\"; \"\"Mumps Vaccine\"\"; \"\"VACCINES FOR ADULTS\"\"; \"\"Influenza Vaccines\"\"; \"\"Pneumococcal Vaccines\"\"; \"\"Meningococcal Vaccines\"\"; \"\"Rabies Vaccine\"\"; \"\"Hepatitis B Vaccine\"\"; \"\"SUMMARY\"\""]
[{"$nulls":4},"\"\"REFERENCES AND NOTES\"\"\"\"6 Liability for the Production and Sale of Vaccines \"\"; \"\"STATE OF THE LAW\"\"; \"\"Experience From the Swine Flu Vaccination Program\"\"; \"\"Recent Trends\"\"; \"\"The Issue of Punitive Damages\"\"; \"\"Summary of the Legal Situation\"\"; \"\"CONSEQUENCES OF THE STATE OF VACCINE INJURY LIABILITY LAW FOR VACCINE PRODUCTION AND INNOVATION\"\"; \"\"REFERENCES AND NOTES\"\"; \"\"7 An Approach to the Problems of Communication, Coordination, and Collaboration in Vaccine Policy\"\"; \"\"HISTORICAL BACKGROUND\"\"; \"\"THE EXISTING STRUCTURE\"\"; \"\"Federal Agency Interactions\"\""]
[{"$nulls":4},"\"\"Public-Private Sector Interactions\"\""]